PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript March 30, 2026 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.2.

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...

Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology ...

Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...

"I'm truly honored to be featured in MSN's "Top 10 Trailblazing Women in 2026!" This recognition reflects not just my journey, but the collective power of science, innovation and purpose-driven ...

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer – Updated Phase 1 ...

Debut Biotech, a company innovating new molecules, is partnering with Image Skincare to launch a new beauty product, CNBC has learned. The San Diego-based company uses biotechnology and artificial ...

Curative Biotechnology, Inc. (OTC: CUBTD) ("Curative” or the "Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases, today announced a reverse ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...